Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 13.7 USD -1.23% Market Closed
Market Cap: 973.4m USD
Have any thoughts about
Zymeworks Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-5.8
Current
-0.7
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5.8
=
Enterprise Value
648.1m USD
/
EBITDA
-111.1m USD
All Countries
All Countries
Close
EBITDA Growth
US
Zymeworks Inc
NASDAQ:ZYME
Average EV/EBITDA: 45.4
Negative Multiple: -5.8 		N/A
US
Abbvie Inc
NYSE:ABBV
16.5
28%
US
Amgen Inc
NASDAQ:AMGN
19.4
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
37%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -537.1 N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
53%
AU
CSL Ltd
ASX:CSL
21.2
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
205.8
N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.2 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-4.9
2-Years Forward
EV/EBITDA
-4.3
3-Years Forward
EV/EBITDA
-4.9

See Also

Summary
ZYME intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZYME stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZYME stock valuation using valuation multiples.
Wall Street Estimates
ZYME price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZYME stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 193,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.